Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.780
-0.020 (-1.11%)
Nov 4, 2024, 4:00 PM EST - Market closed
Entera Bio Revenue
Entera Bio had revenue of $57.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $57.00K, up 159.09% year-over-year.
Revenue (ttm)
$57.00K
Revenue Growth
+159.09%
P/S Ratio
n/a
Revenue / Employee
$3,167
Employees
18
Market Cap
64.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionENTX News
- 5 weeks ago - Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders - GlobeNewsWire
- 2 months ago - Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewsWire
- 3 months ago - Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - GlobeNewsWire
- 6 months ago - Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 - GlobeNewsWire
- 6 months ago - Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research - GlobeNewsWire
- 7 months ago - Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months - GlobeNewsWire